Sanofi SA (ADR) (SNY) is Upgraded by Berenberg to Buy

Sanofi SA (ADR) (SNY) was Upgraded by Berenberg to ” Buy”. Earlier the firm had a rating of “Hold ” on the company shares. Berenberg advised their investors in a research report released on Sep 8, 2016.

Sanofi SA (ADR) opened for trading at $39.37 and hit $39.63 on the upside on Wednesday, eventually ending the session at $39.6, with a gain of 0.56% or 0.22 points. The heightened volatility saw the trading volume jump to 935,437 shares. Company has a market cap of $101,939 M.

Sanofi SA is a healthcare company focused on patient needs and engaged in the research development manufacture and marketing of healthcare products. The Company is organized around three principal activities: Pharmaceuticals Human Vaccines via Sanofi Pasteur and Animal Health via Merial. The Company invests in emerging markets diabetes solutions vaccines consumer health care animal health genzyme and other products. The emerging markets platform includes products from all three of the Company’s principal activities. Under the Company’s Pharmaceuticals business products are grouped into the key fields of diabetes solutions rare diseases multiple sclerosis oncology thrombosis and cardiovascular disease prevention nephrology and bio-surgery. The Human Vaccines activity is operated through Sanofi Pasteur. The Animal Health activity is carried out through Merial.

Sanofi SA (ADR)

Leave a Reply

Sanofi SA (ADR) - Is it time to Sell?

Top Brokerage Firms are advising their investors on Sanofi SA (ADR). Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.